Eatontown, NJ – (GlobeNewswire) – April 23, 2013 – American CryoStem Corporation (OTCQB: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receipt of its first commercial international shipment of adipose tissue for processing and long term cryo-storage.
The master sample was shipped to the Company by BALS (Biomedical and Life Sciences) Institute (BALS), a Hong Kong-based regenerative medicine company and client of Personal Cell Sciences Corp. (PCS), the developer of U-Autologous™ skin care products and formulations. The product uses an individual’s own adult stem cells to create and supply that individual with his or her own personalized anti-aging skin care line.
As part of the previously announced contract manufacturing arrangement between American CryoStem and PCS, American CryoStem is responsible for clinically testing, processing, culturing and storing samples shipped from PCS clients to create Autokine-CM™, the key ingredient in the U-Autologous formulation. BALS Institute has teamed with PCS to ensure the people in Greater China gain access to safe, quality and effective life science technologies through partnerships with leading international corporations.
“American CryoStem has committed extensive resources to establish and perfecting our international shipping methodologies and protocols, ensuring that our processes meet the highest possible standards of regulatory compliance for shipment of biologic materials,” stated John Arnone, Chairman and CEO of American CryoStem. “As a result, our FDA registered laboratory and cryo-storage facilities in New Jersey are now able to send and receive viable tissue samples to and from clients globally.”
Continuing, Arnone added, “The receipt of our first international shipment from BALS Institute marks a very important milestone in our Company’s commercial development and triggers what we expect will be rapid global expansion of our proprietary platform for clinical processing and commercial bio-banking of adipose tissue.”
Mathew Fan, Director of Marketing and Corporate Development for BALS Institute, stated, “We are committed to providing our clients with the most advanced life science treatments and products from around the globe. Working in close collaboration with leading world class companies, such as American CryoStem and Personal Cell Sciences, provides great comfort to our clients, knowing that their stem cells are safely processed, tested and stored in a United States facility for their future use.”
About BALS Institute
Based in Hong Kong, BALS (Biomedical and Life Sciences) Institute, a wholly-owned subsidiary of the Hong Kong-listed company HK Life Science and Technology Group Limited, is a healthcare operational platform providing medical professionals in China access to the latest developments in life science and biomedical technology available in the world today. For more information, please go to www.bals-institute.com.
About Personal Cell Sciences Corp. (PCS)
Personal Cell Sciences Corp. (PCS) is a privately held Life Sciences company dedicated to the development and distribution of personalized Adipose Derived Stem Cell-based anti-aging, topical skin care products formulated using an individual’s own stem cells. PCS not only produces unique skin care products, branded under its U Autologous™ skincare line, but it also helps prepare individuals for the future of Regenerative Medicine by cryogenically storing a clinical grade sample of an individual’s adult stem cells through its affiliation with American CryoStem Corporation. For more information, go to www.personalcellsciences.com.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.